http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008013630-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea8aa6e1d6b1a6533a33cda9d87d8305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7d1f4593cd2ce7bf534abb0b18d717a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0960565afca17814f2e5750f3a4e9f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e21a4c2e7a4f1dd3be5097d6c9a411c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36c11706ea3d36aada1f27d31cd86246
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12
filingDate 2007-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b88417bce26f77b9073264ece3462855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13b24db8ca830cdd3c83e453fa8081ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d415ff1d33141bd4d74dec44315fba2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2e2c51d1821b3d31a8f010a344460a
publicationDate 2009-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008013630-A3
titleOfInvention Calcium aluminosilicate pharmaceutical
abstract A composition and method of treating symptoms of diarrhea that utilize administering an effective amount of an isolated calcium aluminosilicate anti-diarrheal ('CASAD'), wherein the isolated CASAD is substantially free from T4-dioxin and toxic heavy metal contamination, waiting a period of time; and repeating the administration of the composition until the symptoms of diarrhea are mitigated. The symptoms of diarrhea may be associated with chronic or infectious diseases, inflammatory proteins, treatment using drugs, or treatment using a chemotheraputic agent in a subject in need of treatment. The isolated CASAD is capable of binding inflammatory proteins, drug metabolites, and chemotherapeutic agents. The isolated CASAD can be administered in any suitable form, such as in tablet, powder, or suspension form, and can be administered by any suitable route, such as orally.
priorityDate 2006-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8606633-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006067945-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007011825-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID157010056
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453688467

Total number of triples: 33.